Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital.

Autor:	Raghu Subramanian C; Department of Medicine, Guthrie Clinic/Robert Packer Hospital, Sayre, PA, USA.; Washington Hospital Healthcare System, Fremont, CA, USA., Talluri S; Department of Medicine, Guthrie Clinic/Robert Packer Hospital, Sayre, PA, USA., Khan SU; Department of Medicine, Guthrie Clinic/Robert Packer Hospital, Sayre, PA, USA.; Department of Medicine, West Virginia University, Morgantown, WV, USA., Katz JA; Division of Gastroenterology and Liver Diseases, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Georgetson M; Division of Gastroenterology, Department of Medicine, Guthrie Clinic, Sayre, PA, USA., Sinh P; Division of Gastroenterology, Department of Medicine, Guthrie Clinic, Sayre, PA, USA.; Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Jazyk:	angličtina
Zdroj:	Gastroenterology research [Gastroenterology Res] 2020 Aug; Vol. 13 (4), pp. 138-145. Date of Electronic Publication: 2020 Aug 14.
DOI:	10.14740/gr1275
Abstrakt:	Background: Cure rates of Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities. Methods: Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months). Results: Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late). Conclusions: This case series is a description of our center's initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities. Competing Interests: Dr Jeffry A Katz: 1) Prometheus Labs advisory board; 2) Boerhinger-Ingelheim advisory board. No disclosures for rest of the authors. (Copyright 2020, Raghu Subramanian et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu